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Abstract 
 
Objective: To explore, from the patient-perspective, the beneficial and adverse 
effects (AEs) of glucocorticoids (GCs) in patients with rheumatic diseases, to be 
used in the development of a patient reported outcome measure (PROM).  
Methods: A cross-sectional survey, capturing benefits and AEs of GC use, was 
administered to two groups of patients: 1.Those attending a tertiary rheumatology 
clinic with various rheumatic diseases who had used GCs within the past year, 
2.Patients from the Hospital for Special Surgery RA database.  
Results: Cohort 1 had 55 GC-users and cohort 2 had 95 GC-users and 29 non-
users. The majority of GC-users in both cohorts reported  AE (100%, 86%). The 
AE prevalence per person was 50% higher in cohort 1 compared to GC-users in 
cohort 2 (7.7 vs 5.3, AE ratio 1.5, 95%CI 1.3-1.7) and 2-fold greater in cohort 2 GC-
users compared to GC non-users (5.3 vs 2.6, AE ratio 2.0, 95%CI 1.6-2.6). In both 
cohorts, AEs identified as ³ZRUVW´ by GC users included skin thinning/easy bruising, 
sleep disturbance, mood disturbance and change in facial shape. Most felt GCs 
helped WKHLUGLVHDVHµDORW¶%/62%) and that the benefits were greater than the 
AEs (55%/64%). Many AEs were more frequent in GC users than non-users. 
Conclusions: Patients receiving GC therapy for rheumatic conditions report a large 
number of AEs and those that have the greatest life impact are often difficult for 
physicians to measure. These results will inform the development of a PROM to 
capture the effects of GCs from the patient-perspective. 
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Introduction 
Glucocorticoids (GCs) are frequently used to treat rheumatic conditions including 
inflammatory arthritis, connective tissue disorders, vasculitis and polymyalgia 
rheumatica [1]. Whilst they are effective anti-inflammatory agents, they are also 
associated with many potential adverse effects (AEs) such as skin thinning, easy 
bruising, weight gain, osteoporosis, diabetes, hypertension, infection and cataract. 
However, not all patients exposed to GCs will develop AEs and there is currently no 
standardised measure of the benefits and AEs that are important to patients.  The 
EULAR Taskforce on GC therapy has published two systematic reviews concluding 
that there is a need to systematically capture GC AEs in a standardised manner [2, 
3]. EULAR recommendations for monitoring GC AEs in clinical trials and daily 
practice suggested that new tools be developed for assessing adverse events [4].  
This has led to the very recent development of the glucocorticoid toxicity index (GTI), 
which measures the physiological AEs (clinical signs and biomarkers) of GC use[5]. 
The GTI focuses on items that are measurable in the clinic such as glucose 
tolerance, BMI and blood pressure. 
,QFUHDVLQJO\DSDWLHQW¶VH[SHULHQFHRIWUHDWPHQWDQGFDUHhas been recognised as 
an important quality indicator. This has led to an expansion in the development and 
DSSOLFDWLRQRITXHVWLRQQDLUHVWRPHDVXUHKHDOWKDQGLOOQHVVIURPWKHSDWLHQW¶V
perspective. Patient reported outcome measures (PROMs) provide unique insight 
into the way patients perceive their health and the impact that treatments have on 
their quality of life [6, 7]. PROMs involve patients in clinical decision-making, can 
improve doctor-patient communication about treatment and ultimately lead to better 
patient outcomes[7]. At present, there is no PROM to measure the risks, benefits 
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and experience of systemic GC use from the patient perspective [8].  Patients may 
perceive important effects differently than physicians [9], making it important to 
understand both the impact of GC use from the patient perspective in addition to the 
physiological impact measured by the GTI.   
The first step in developing a PROM for the impact of GCs, is to undertake 
qualitative and quantitative pilot work that provides insight into the aspects of GC 
treatment that are important to patients, so that these can be captured as items in 
any future measurement tool.  The aim of this pilot study was to determine the AEs 
related to GCs in two groups of GC users and to explore which GC effects are 
important to patients. A secondary aim was to compare AEs reported by RA patients 
exposed and not exposed to GCs. 
Methods 
A cross-sectional, questionnaire-based survey was carried out in two cohorts, in 
Australia and the USA. In Australia, the study was approved by The Queen Elizabeth 
Hospital Human Research Ethics Committee, reference number: 
HREC/14/TQEHLMH/209. In the USA, the cohort was approved by the Hospital for 
Special Surgery Ethics Review Board, reference number: 2014-234-CR2. 
Participants 
Participants in cohort 1 (Australian cohort) attended a tertiary rheumatology clinic 
with various rheumatic diseases and were taking an oral GC currently or within the 
past 12 months. Potential participants were identified from the departmental 
electronic outpatient letters, ZKLFKDUHVHQWWRDSDWLHQW¶V*3DIWHUHDFKRXWSDWLHQW
visit and include a summary of the diagnoses and medications. All letters from the 
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past 12 months were assessed by two reviewers (RJB, CR), and a random selection 
of eligible patients were mailed out a participant information sheet, consent form and 
a copy of the questionnaire with a reply paid return envelope. Cohort 2 (USA cohort) 
was from the Hospital for Special Surgery (HSS) rheumatoid arthritis (RA) database 
and included both GC users and non-users. Cases included in the database are 
identified from the HSS practice records by ICD-9 code 714.0 and confirmed by chart 
review. Cases meeting ACR/EULAR criteria for RA are recruited at a clinic visit or via 
mail and are included after giving consent, at which time they complete a brief 
survey and agree to be contacted for further studies.  The questionnaire was 
distributed to patients on the database with a valid email address. 
Questionnaire 
A pilot questionnaire was developed in order to explore patient-reported GC AEs and 
assess the risks and benefits of GCs from the patient perspective. It included a 
checklist of 19 known AEs and an open-HQGHGTXHVWLRQDERXWSUHVHQFHRIµRWKHU*&
VLGHHIIHFWV¶The questionnaire was designed to be as inclusive as possible, whilst 
balancing the burden of data entry by keeping the checklist relatively concise. 
Checklist items included AEs cited frequently in the literature as well as those 
occurring frequently in the authors¶ clinical experience. In addition, all participants 
ZHUHDVNHGWRUDWHWKHWKUHHµZRUVW¶$(V3DUWLFLSDQWVH[SRVHGWR*&VZHUHDVNHGWR
LQGLFDWHZKHWKHU*&WKHUDS\KHOSHGµDORW¶µDOLWWOH¶µQRWVXUH¶RUµQRWDWDOO¶DQG 
whether the AEs they experienced were worse than the benefits of treatment 
(Yes/No/Not sure).  The questionnaire was not developed to be a PROM itself, but 
rather as a format by which to capture information that will inform the development of 
a PROM in the future [8]. (A copy of the questionnaire can be found in file, 
Supplemental Digital Content 1) 
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Analysis 
Descriptive statistics were used to summarise cohort demographics, the frequency of 
the individual AEs on the checklist as well as those considered to be the worst AEs. 
The median number of AEs experienced by each patient (AE prevalence) was 
compared between cohorts using Poisson regression and the number of patients to 
report at least one AE was analysed using chi-square. The degree to which 
SDUWLFLSDQW¶VIHOW*&VKHOSHGWKHLUFRQGLWLRQZDVDVVHVVHGE\FRPSDULQJthe ordinal 
trend between groups using the Cochran Armitage exact test. A chi-square analysis 
was carried out for the comparison of GC AEs and benefits. Within cohort 2, AEs 
reported by GC users and GC non-XVHUVZHUHFRPSDUHGE\)LVKHU¶VH[DFWWHVWAll 
analyses were carried out in R version 3.2.3 [10]. 
Results 
In cohort 1 (Australia), 88 questionnaires were distributed and 55 (63%) were 
returned. In cohort 2 (US), there were 227 questionnaires distributed to those with a 
valid email address, with 124 (55%) returned. All patients in cohort 1 were GC users 
and in cohort 2, 95 (77%) had ever used GCs (GC-users) and 29 (23%) had never 
used GCs (GC non-users). Demographics and diagnoses are summarized in Table 
1. For Cohort 1, the 33 patients who declined to participate were younger (median 
age 63, IQR 51-75 vs median age 68 IQR 60-76), and a greater proportion was 
female (27/33, 82% vs 39/55, 71%). For Cohort 2, the 103 patients who did not 
participate were also slightly younger (median 60, IQR 52-70 vs median 63, IQR 53-
71), with a similar proportion of females (91/103, 88% vs 103/124, 83%).  RA 
duration was similar in non-participants (median 9.5 years, IQR 4.5-18.0 vs. median 
 8 
9.6 years, IQR 5.5-17.5) and fewer were glucocorticoid users at the time of the 
survey (23/103, 22% vs 35/124, 28%).  
 
The AE prevalence per person was 50% higher in in cohort 1 compared to GC users 
in cohort 2 (7.7 vs 5.3, AE ratio 1.5, 95%CI 1.3-1.7) and 2-fold greater in cohort 2 
GC-users compared to GC non-users (5.3 vs 2.6, AE ratio 2.0, 95%CI 1.6-2.6). All 
patients in cohort 1 reported at least one GC AE compared to 86% of GC-users in 
Cohort 2 (p=0.002).  
The frequency of patient reported AEs and worst AEs are shown in Figure 1.  The 
most frequent AEs were similar amongst patients in cohort 1 (thin skin/easy bruising, 
weight gain, sleep disturbance and stomach upset/gastric reflux) and GC-users in 
cohort 2 (sleep disturbance, thin skin/easy bruising and weight gain). The most 
frequent AEs in cohort 2 GC non-users were sleep disturbance, stomach 
upset/gastric reflux and muscle weakness. Worst AEs were dependent on the AE 
frequency and included thin skin/easy bruising (9/45), weight gain (9/36) and sleep 
disturbance (9/30) in cohort 1. The worst AEs for GC-users in cohort 2 included 
weight gain (13/40), sleep disturbance (8/49), stomach upset/gastric reflux (8/38) 
and muscle weakness (8/34). GC non-users noted swelling of the feet or ankles 
(4/6), weakness of muscles (3/8), increased appetite (2/3) and thrush in the mouth 
(2/2) as the worst AEs. Additional AEs attributed to GCs in either cohort are shown in 
Figure, Supplemental Digital Content 2.  
In both GC use cohorts, the majority (78IHOW*&VKHOSHGWKHLUGLVHDVHµDORW¶
IHOWWKH\KHOSHGµDOLWWOH¶ZHUHµQRWVXUH¶DQGIHOW*&VGLG
not help at all, with no difference between groups (ordinal p=1.0). Most participants 
in cohort 1 (55%) and cohort 2 (64%) felt the benefits of treatment were greater than 
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the AEs, with no difference between groups (p=0.67). In Cohort 2, AEs including: 
weight gain, thin skin or easy bruising, high blood sugars, broken bones, change in 
shape of face, change in shape of body and increased appetite were more frequently 
reported by GC users compared to GC non-users (p<0.05) as shown in Table 2. 
Discussion 
This study has demonstrated that many AEs that are important to patients are more 
common in GC users compared to non-users, and include symptoms that are difficult 
to capture using conventional physiological measures. In addition, a difference in the 
AE rate among cohort 1 (mixed rheumatic diagnoses) and GC users in cohort 2 (RA) 
was detected, possibly reflecting the different demographics, diagnoses and 
unmeasured differences in the dose and duration of GC treatment.  
Many studies looking at GC AEs have focussed on AEs that are easier to measure 
such as osteoporosis, fractures and infection. However, few studies have also 
captured patient-reported GC AEs. In a cross-sectional study of UK patients with 
asthma (n=233), 88% reported one or more AEs, with bruising (67%) and weight 
gain (67%) most common [11]. In a French cohort study of 80 participants on long 
term systemic GCs, 71% reported one or more AEs, with change in face shape 
reported as the most distressing (39%) [12]. A cross-sectional study of UK patients 
with asthma, COPD and fibrosing alveolitis (n=367) found that bruising (73%) and 
muscle weakness (60%) were the most common GC AEs [13]. A UK based case-
control study of PMR and GCA found that 23/35 (66%) participants reported one or 
more AEs, with weight gain (26%) and skin changes (26%) most common [14].  
In the largest study to date, Curtis et al. included a population cohort of 2167 long-
term GC users from the US, of which 90% reported at least one from a list of eight 
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potential AEs [15]. The most common GC AEs included weight gain, skin bruising or 
thinning and sleep problems, similar to the current study. However, the current study 
examined 19 rather than 8 items, in addition to a free-text question to capture 
additional AEs attributed to GC use by patients. The current study also differed from 
the previous study in its comparison of AEs reported by RA patients with and without 
GC therapy, and in that patients ZHUHDVNHGWRSULRULWLVHWKHWKUHHµZRUVW¶AEs. Lastly, 
in the current study, the survey was administered in two different English-speaking 
countries, which is important for cross-cultural generalizability.  
Another cross-sectional study looking at GC AEs that are important to patients was 
recently carried out in a novel cohort of online health users in the UK[16]. In this 
population, weight gain was deemed the most important AE followed by insomnia 
and moon face. The design and unique setting of this study provide additional insight 
into the patient experience of GC AEs. The results complement the findings of this 
study and will also be useful in the development of a future PROM. 
Limitations of the study include potential biases associated with survey-based 
research. There may be a response bias, with fundamental differences in the 
experience of responders and non-responders; indeed, in Cohort 2, fewer 
glucocorticoid non-users responded to the survey.  Also in cohort 2, only those with 
valid email addresses were included and there may be differences between people 
ZKRXVHWHFKQRORJLHVDQGWKRVHZKRGRQ¶WThere is also the potential for recall bias, 
with those who received more recent GC therapy more likely to recall a greater 
number of AEs. Other limitations of this study include the small sample size and that 
the questionnaire was only available in English. Whilst the checklist was created to 
capture many common GC AEs, some AEs, such as infections other than oral and 
vaginal thrush were not included in order to minimise any burden of data entry. The 
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free-text section was included to capture other AEs not on the checklist, however 
these may have been reported less than those visible on the checklist.  
Strengths of this study include its inclusion of two different cohorts and its 
comparison of AEs amongst GC users and non-users from the same cohort. The 
results of this study will be used, in conjunction with ongoing qualitative work in 
different disease cohorts, to develop potential items for inclusion in a PROM. These 
potential items will then be compiled and patient and clinician experts will be 
engaged to determine the most appropriate items to be included in the final PROM, 
which will then be properly developed and validated. Such a PROM will provide 
patients with an effective means by which to communicate with their treatment team 
about the impact of GC treatment. 
Conclusion 
This cross-sectional study has increased our understanding of the impact of GC 
therapy form the patient perspective and is the first step in the development of a 
PROM. Patient-reported GC AEs were common amongst GC users, however the 
benefits of treatment were felt to outweigh the AEs. In addition, many patient-
reported AEs, were more frequent among RA GC users than non-users. 
Key Points 
x Patient-reported glucocorticoid (GC) adverse effects (AEs) occurred in 86-100% 
of GC users. 
x Many GC AEs that are important to patients are poorly captured by current 
physiological measures, including thin skin and easy bruising, sleep disturbance 
and stomach upset/gastric reflux. 
x Most patients felt that GCs are effective at controlling their disease and that the 
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benefits of treatment outweigh the AEs. 
x Many patient-reported AEs, were more frequent among RA GC users than non-
users  
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Tables 
Table 1. Baseline Demographics and Diagnoses  
Table 2. Differences between AEs reported by GC Users and GC Non-Users in 
Cohort 2 
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Figure Legends 
Figure 1. Frequency of Glucocorticoid Adverse Effects and Worst Adverse Effects in 
A. Cohort 1, n=55, B. Cohort 2 GC-users, n=95 and C. Cohort 2 GC Non-users, 
n=29. 
Supplemental Digital Content 
Supplemental Digital Content 1: File. Glucocorticoid Adverse Effects Questionnaire 
Supplemental Digital Content 2: Figure. Other AEs attributed to GC use by patients 
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